New publication on CD8 PET imaging
Monitoring CD8a+ T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [64Cu]NOTA-CD8a PET Imaging
Current response assessment systems for cancer patients receiving immunotherapy are limited. This is due to the associated inflammatory response that may confound the conventional morphological response evaluation criteria in solid tumors and metabolic positron emission tomography (PET) response criteria in solid.
Recently, novel PET imaging techniques using radiolabeled antibodies and fragments have emerged as a particularly sensitive and specific modality for quantitative tracking of immune cell dynamics. Therefore, we sought to investigate the utility of Cu-64 labeled F(ab)′2 fragments for in vivo detection of CD8a+ T cells as a prognostic imaging biomarker of response to immunotherapy in an immunocompetent mouse model of colorectal cancer.
In the publication we demonstrate how PET imaging of CD8+ T cells were able to distinguish responders and non-respondors prior to treatment-induceds changes in tumor volume among. To read more please see full article.
Poster presentation at the AACR annual meeting 2021
Minerva Imaging are happy to share the use of our intracranial breast […]Read story
Minerva Imaging is presenting at the AACR-NCI-EORTC 2019
Minerva Imaging is presenting at the AACR-NCI-EORTC Conference 2019Read story